$0.26
(Market cap
$8,256 Mln
Revenue (TTM)
$800 Mln
P/E Ratio
19.7
P/B Ratio
14.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
62.6
-
Debt to Equity
1.2
-
Book Value
$--
-
EPS
$2.7
-
Face value
--
-
Shares outstanding
153,083,580
10 Years Aggregate
CFO
$-1,214.56 Mln
EBITDA
$-1,438.86 Mln
Net Profit
$-1,500.88 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
| 89.0 | 8.3 | 50.6 | 92.1 | 74.5 | 13.8 | 24.1 |
|
BSE Sensex
| -9.6 | -2.0 | 3.1 | -4.7 | 5.4 | 6.0 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
| -1.0 | 75.4 | 44.4 | -37.7 | -63.5 | 368.6 | 170.7 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
TG Therapeutics (TGTX)
|
56.4 | 8,255.8 | 799.5 | 441.5 | 14.0 | 70.5 | 19.7 | 14.1 |
| 84.3 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 265.6 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 71.2 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 58.4 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 109.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 366.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 543.3 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.3 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 357.4 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 |
Shareholding Pattern
View DetailsAbout TG Therapeutics (TGTX)
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides... BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Ublituximab IV, glycoengineered anti-CD20 mAb for the treatment of relapsing MS; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Jiangsu Hengrui Medicine Co. The company was incorporated in 1993 and is based in Morrisville, North Carolina. Read more
-
Chairman, CEO & President
Mr. Michael S. Weiss Esq.
-
Chairman, CEO & President
Mr. Michael S. Weiss Esq.
-
Headquarters
Morrisville, NC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for TG Therapeutics (TGTX)
What is the current share price of TG Therapeutics Inc (TGTX) Today?
The share price of TG Therapeutics Inc (TGTX) is $56.35 (NASDAQ) as of 02-Sep-2026 14:37 EDT. TG Therapeutics Inc (TGTX) has given a return of 74.47% in the last 3 years.
What is the current PB & PE ratio of TG Therapeutics Inc (TGTX)?
The P/E ratio of TG Therapeutics Inc (TGTX) is 19.68 times as on 28-Aug-2026.
The P/B ratio of TG Therapeutics Inc (TGTX) is 14.12 times as on 28-Aug-2026, a 173 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
10.62 |
7.33 |
2024 |
206.28 |
21.69 |
2023 |
192.87 |
15.23 |
2022 |
-7.25 |
27.69 |
2021 |
-7.24 |
10.62 |
What is the 52 Week High and Low of TG Therapeutics Inc (TGTX)?
The 52-week high and low of TG Therapeutics Inc (TGTX) are Rs 59.30 and Rs 26.76 as of 03-Sep-2026.
What is the market cap of TG Therapeutics Inc (TGTX)?
TG Therapeutics Inc (TGTX) has a market capitalisation of $ 8,256 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in TG Therapeutics Inc (TGTX)?
Before investing in TG Therapeutics Inc (TGTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.